Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bolt Biotherapeutics, Inc. (BOLT)
USD4.12
+0.07 (+1.73%)
US NASDAQ Healthcare Biotechnology
Address
900 Chesapeake Drive 94063
Redwood City, CA, US
Redwood City, CA, US
CEO
William Quinn
Website
boltbio.com
IPO
2021-02-05
CIK 1641281 ISIN US0977022039
Description
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.12
+0.07 (+1.73%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
29.7K
Beta
1.17
Float Shares
1.55M
Free Float %
80.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.70% | +2.58% | +2.58% | -3.43% | +1.70% | -12.61% | -30.72% | -87.74% | -98.70% | -99.26% | -99.26% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Hold
Price Targets & DCF
Current price
4.12
Low
1.00
-75.7%
Consensus
4.00
-2.9%
Median
4.00
-2.9%
High
7.00
+69.9%
Ratings Trend (MoM)
50% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
7.00
+69.9%
|
| All Time | 2 |
4.00
-2.9%
|
Quality scores
Altman Z-Score
-14.88
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+0.1% Q1'26: -97.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-981.8% Q1'26: -1,386.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-589.1% Q1'26: -30,857.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-450.1% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-157.7% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-95.1% ★ Q1'26: -56.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.69× Q1'26: -0.73× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
231.0K
est: 265.5K (-13.0%)
|
1.26M
est: 1.96M (-35.7%)
|
5.73M
est: 5.68M (+0.9%)
|
7.88M
est: 11.17M (-29.5%)
|
7.69M
est: 8.47M (-9.2%)
|
7.70M
est: 5.87M (+31.2%)
|
3.00M
857.1K – 5.14M
-48.8% YoY
|
7.00M
2.00M – 12.00M
+133.3% YoY
|
8.00M
2.29M – 13.71M
+14.3% YoY
|
8.00M
2.29M – 13.71M
+0.0% YoY
|
8.00M
2.29M – 13.71M
+0.0% YoY
|
| EBITDA |
-48.57M
est: -265.5K (-18,194.2%)
|
-91.60M
est: -1.96M (-4,571.3%)
|
-88.66M
est: -5.68M (-1,461.2%)
|
-74.34M
est: -11.17M (-565.8%)
|
-66.46M
est: -8.47M (-684.4%)
|
-33.14M
est: -5.87M (-465.1%)
|
-3.00M
-5.14M – -857.1K
+48.8% YoY
|
-7.00M
-12.00M – -2.00M
-133.3% YoY
|
-8.00M
-13.71M – -2.29M
-14.3% YoY
|
-8.00M
-13.71M – -2.29M
+0.0% YoY
|
-8.00M
-13.71M – -2.29M
+0.0% YoY
|
| EBIT |
-49.18M
est: -265.5K (-18,424.3%)
|
-92.79M
est: -1.96M (-4,632.2%)
|
-90.32M
est: -5.68M (-1,490.6%)
|
-76.20M
est: -11.17M (-582.4%)
|
-68.24M
est: -8.47M (-705.4%)
|
-34.63M
est: -5.87M (-490.5%)
|
-3.00M
-5.14M – -857.1K
+48.8% YoY
|
-7.00M
-12.00M – -2.00M
-133.3% YoY
|
-8.00M
-13.71M – -2.29M
-14.3% YoY
|
-8.00M
-13.71M – -2.29M
+0.0% YoY
|
-8.00M
-13.71M – -2.29M
+0.0% YoY
|
| Net Income |
-60.73M
est: -2.90B (+97.9%)
|
-98.59M
est: -2.39B (+95.9%)
|
-88.10M
est: -1.78B (+95.0%)
|
-69.20M
est: -3.26M (-2,025.4%)
|
-63.12M
est: -60.15M (-4.9%)
|
-33.38M
est: -39.69M (+15.9%)
|
-37.36M
-79.05M – -2.93M
+5.9% YoY
|
-23.75M
-89.22M – -3.30M
+36.4% YoY
|
-30.00M
-111.22M – -4.12M
-26.3% YoY
|
-66.44M
-128.13M – -4.75M
-121.5% YoY
|
-74.97M
-144.58M – -5.35M
-12.8% YoY
|
| SGA |
9.06M
est: 3.35M (+170.4%)
|
18.39M
est: 24.73M (-25.6%)
|
22.93M
est: 71.62M (-68.0%)
|
22.53M
est: 57.29M (-60.7%)
|
18.46M
est: 43.47M (-57.5%)
|
13.80M
est: 30.09M (-54.2%)
|
15.39M
4.40M – 26.39M
-48.8% YoY
|
35.91M
10.26M – 61.57M
+133.3% YoY
|
41.04M
11.73M – 70.36M
+14.3% YoY
|
41.04M
11.73M – 70.36M
+0.0% YoY
|
41.04M
11.73M – 70.36M
+0.0% YoY
|
| EPS |
-1.99
est: -76.07 (+97.4%)
|
-2.79
est: -62.56 (+95.5%)
|
-2.30
est: -47.17 (+95.1%)
|
-1.83
est: -1.74 (-5.1%)
|
-1.65
est: -32.27 (+94.9%)
|
-17.85
est: -21.23 (+15.9%)
|
-21.92
-42.27 – -1.57
-3.3% YoY
|
-24.74
-47.71 – -1.77
-12.9% YoY
|
-30.84
-59.48 – -2.20
-24.7% YoY
|
-35.53
-68.52 – -2.54
-15.2% YoY
|
-40.09
-77.32 – -2.86
-12.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-26.22M
OE per share TTM
-7.16
Owner's Yield
-32.64%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
510.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
21
Total invested
3.30M
Insider transactions (90d)
0
Beneficial owners (>5%)
26
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Novo Holdings A/S | 4.50M | 13.00% | 4.50M | — | 4.50M | — | CO | — | 2021-02-11 | ↗ |
| 2 | Dr. James I. Healy (“Healy”) | 2.75M | 8.00% | — | 2.75M | — | 2.75M | IN | U.S. Citizen | 2021-02-16 | ↗ |
| 3 | Dr. Maha Katabi (“Katabi”) | 2.75M | 8.00% | — | 2.75M | — | 2.75M | IN | Canadian Citizen | 2021-02-16 | ↗ |
| 4 | Dr. Michael F. Powell (“Powell”) | 2.75M | 8.00% | — | 2.75M | — | 2.75M | IN | U.S. Citizen | 2021-02-16 | ↗ |
| 5 | Sofinnova Management X, L.L.C. (“SM X”) | 2.75M | 8.00% | 2.75M | — | 2.75M | 10.00 | OO | Delaware | 2021-02-16 | ↗ |
| 6 | Sofinnova Venture Partners X, L.P. (“SVP X”) | 2.75M | 8.00% | 2.75M | — | 2.75M | — | PN | Delaware | 2021-02-16 | ↗ |
| 7 | Peter Kolchinsky | 2.38M | 6.50% | — | 2.38M | — | 2.38M | HC, IN | Delaware | 2021-04-07 | ↗ |
| 8 | RA Capital Management, L.P. | 2.38M | 6.50% | — | 2.38M | — | 2.38M | IA, PN | Delaware | 2021-04-07 | ↗ |
| 9 | Rajeev Shah | 2.38M | 6.50% | — | 2.38M | — | 2.38M | HC, IN | Delaware | 2021-04-07 | ↗ |
| 10 | Vivo Capital VIII, LLC | 2.27M | 6.60% | 2.27M | — | 2.27M | — | OO | Delaware | 2021-02-18 | ↗ |
| 11 | Aaron Cowen | 2.23M | 6.00% | — | 2.23M | — | 2.23M | HC, IN | Delaware | 2021-11-29 | ↗ |
| 12 | Averill Master Fund, Ltd. | 2.23M | 6.00% | — | 2.23M | — | 2.23M | CO | Delaware | 2021-11-29 | ↗ |
| 13 | Suvretta Capital Management, LLC | 2.23M | 6.00% | — | 2.23M | — | 2.23M | IA, OO | Delaware | 2021-11-29 | ↗ |
| 14 | RA Capital Healthcare Fund, L.P. | 1.92M | 5.30% | — | 1.92M | — | 1.92M | PN | Delaware | 2021-04-07 | ↗ |
| 15 | Pivotal bioVenture Partners Fund I G.P., L.P. | 1.89M | 5.50% | — | 1.89M | — | 1.89M | PN | — | 2021-02-17 | ↗ |
| 16 | Pivotal bioVenture Partners Fund I U.G.P., Ltd. | 1.89M | 5.50% | — | 1.89M | — | 1.89M | CO | — | 2021-02-17 | ↗ |
| 17 | Pivotal bioVenture Partners Fund I, L.P. | 1.89M | 5.50% | — | 1.89M | — | 1.89M | PN | — | 2021-02-17 | ↗ |
| 18 | Vivo Panda, LLC | 1.45M | 4.20% | 1.45M | — | 1.45M | — | OO | Delaware | 2021-02-18 | ↗ |
| 19 | Vivo Opportunity, LLC | 150.0K | 0.40% | 150.0K | — | 150.0K | — | OO | Delaware | 2021-02-18 | ↗ |
| 20 | CALC IV LP | 10.00 | 12.00% | — | 412.00 | — | — | HC, PN | Delaware | 2021-02-19 | ↗ |
| 21 | Citadel Securities GP LLC | 10.00 | 12.00% | — | 412.00 | — | — | HC, OO | Delaware | 2021-02-19 | ↗ |
| 22 | Citadel Securities LLC | 10.00 | 12.00% | — | 412.00 | — | — | BD, OO | Delaware | 2021-02-19 | ↗ |
| 23 | Citadel Advisors Holdings LP | 10.00 | 8.10% | — | 2.94M | — | — | HC, PN | Delaware | 2021-02-19 | ↗ |
| 24 | Citadel Advisors LLC | 10.00 | 8.10% | — | 2.94M | — | — | IA, HC, OO | Delaware | 2021-02-19 | ↗ |
| 25 | Citadel GP LLC | 10.00 | 8.10% | — | 2.94M | — | — | HC, OO | Delaware | 2021-02-19 | ↗ |
| 26 | Kenneth Griffin | 10.00 | 8.10% | — | 2.94M | — | — | HC, IN | Delaware | 2021-02-19 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
21
-3 vs prev Q
New positions
3
Closed positions
6
Increased
7
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 20.5K +20.5K (+100.0%) | 112.09M +112.1M (+100.0%) | 1.07% +1.068 pp | 0.10% +0.096 pp | USD5.47 +0.0% | 1 qtrs NEW |
| 2 | SOFINNOVA INVESTMENTS, INC. | 137.7K +— (+0.0%) | 753.1K +20.4K (+2.8%) | 7.18% -0.007 pp | 0.03% -0.008 pp | USD5.77 -5.2% | 3 qtrs — |
| 3 | PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC | 94.6K +— (+0.0%) | 517.1K +14.0K (+2.8%) | 4.93% -0.005 pp | 0.20% -0.091 pp | USD5.77 -5.2% | 3 qtrs — |
| 4 | VIVO CAPITAL, LLC | 72.4K -103.7K (-58.9%) | 396.0K -540.7K (-57.7%) | 3.77% -5.409 pp | 0.03% -0.050 pp | USD5.77 -5.2% | 3 qtrs — |
| 5 | NAN FUNG GROUP HOLDINGS LTD | 58.3K +— (+0.0%) | 319.0K +8.6K (+2.8%) | 3.04% -0.003 pp | 0.29% -0.235 pp | USD5.77 -5.2% | 3 qtrs — |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 55.0K +26.4K (+92.2%) | 300.9K +148.6K (+97.6%) | 2.87% +1.374 pp | 0.00% +0.000 pp | USD5.54 -1.3% | 3 qtrs — |
| 7 | — | 38.0K +38.0K (+100.0%) | 207.8K +207.8K (+100.0%) | 1.98% +1.980 pp | 0.26% +0.258 pp | USD5.47 +0.0% | 1 qtrs NEW |
| 8 | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 36.0K -1.0 (0.0%) | 196.7K +5.3K (+2.8%) | 1.87% -0.002 pp | 0.04% +0.017 pp | USD5.77 -5.2% | 3 qtrs — |
| 9 | PFIZER INC | 31.3K +— (+0.0%) | 171.2K +4.6K (+2.8%) | 1.63% -0.002 pp | 0.07% +0.034 pp | USD5.77 -5.2% | 3 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 18.8K +270.0 (+1.5%) | 103.1K +4.4K (+4.5%) | 0.98% +0.013 pp | 0.00% +0.000 pp | USD5.77 -5.2% | 3 qtrs — |
| 11 | SHAY CAPITAL LLC | 15.3K -686.0 (-4.3%) | 83.5K -1.4K (-1.6%) | 0.80% -0.037 pp | 0.01% +0.001 pp | USD5.32 +2.8% | 2 qtrs — |
| 12 | VANGUARD GROUP INC | 10.2K -24.1K (-70.3%) | 55.8K -126.3K (-69.4%) | 0.53% -1.255 pp | 0.00% +0.000 pp | USD5.77 -5.2% | 3 qtrs — |
| 13 | BLACKROCK, INC. | 9.7K +— (+0.0%) | 53.1K +1.4K (+2.8%) | 0.51% -0.001 pp | 0.00% +0.000 pp | USD5.77 -5.2% | 3 qtrs — |
| 14 | MORGAN STANLEY | 3.1K +— (+0.0%) | 17.1K +463.0 (+2.8%) | 0.16% 0.000 pp | 0.00% +0.000 pp | USD5.77 -5.2% | 3 qtrs — |
| 15 | TOWER RESEARCH CAPITAL LLC (TRC) | 723.00 +464.0 (+179.2%) | 4.0K +2.6K (+186.9%) | 0.04% +0.024 pp | 0.00% +0.000 pp | USD5.58 -2.0% | 3 qtrs — |
| 16 | UBS GROUP AG | 515.00 +512.0 (+17,066.7%) | 2.8K +2.8K (+17,500.0%) | 0.03% +0.027 pp | 0.00% +0.000 pp | USD5.47 +0.0% | 3 qtrs — |
| 17 | CITIGROUP INC | 256.00 +256.0 (+100.0%) | 1.4K +1.4K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.000 pp | USD5.47 +0.0% | 1 qtrs NEW |
| 18 | JPMORGAN CHASE & CO | 42.00 +— (+0.0%) | 230.00 +7.0 (+3.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.76 -5.0% | 3 qtrs — |
| 19 | BANK OF AMERICA CORP /DE/ | 31.00 +— (+0.0%) | 169.00 +4.0 (+2.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.74 -4.7% | 3 qtrs — |
| 20 | SBI SECURITIES CO., LTD. | 10.00 +— (+0.0%) | 55.00 +2.0 (+3.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.70 -4.0% | 3 qtrs — |
| 21 | BARCLAYS PLC | 6.00 +— (+0.0%) | 33.00 +1.0 (+3.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.67 -3.5% | 3 qtrs — |
| 22 | TANG CAPITAL MANAGEMENT LLC | — -66.9K (-100.0%) | — -355.8K (-100.0%) | 0.00% -3.488 pp | 0.00% -0.014 pp | USD— | 3 qtrs SOLD |
| 23 | SAMSARA BIOCAPITAL, LLC | — -48.8K (-100.0%) | — -259.8K (-100.0%) | 0.00% -2.546 pp | 0.00% -0.034 pp | USD— | 3 qtrs SOLD |
| 24 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | — -16.6K (-100.0%) | — -88.5K (-100.0%) | 0.00% -0.868 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 25 | DRW SECURITIES, LLC | — -12.3K (-100.0%) | — -65.6K (-100.0%) | 0.00% -0.643 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 26 | SQUAREPOINT OPS LLC | — -14.8K (-100.0%) | — -78.9K (-100.0%) | 0.00% -0.774 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 27 | SALEM INVESTMENT COUNSELORS INC | — -2.0 (-100.0%) | — -11.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 36.2K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
93.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+93,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-28 | Yonehiro Grant | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 10,000 | 6.71 | 67.1K | 10,000 | D | ↗ |
| 2026-01-28 | Quinn William P. | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 20,000 | 6.71 | 134.2K | 20,000 | D | ↗ |
| 2026-01-28 | Nemec Sarah | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 8,000 | 6.71 | 53.7K | 8,000 | D | ↗ |
| 2025-12-12 | Yonehiro Grant | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 822 | 5.44 | 4.5K | 822 | D | ↗ |
| 2025-12-12 | Quinn William P. | Director / Officer | D-Return | D | Employee Stock Option (Right to Buy) | 11,749 | 25.40 | 298.4K | 0 | D | ↗ |
| 2025-12-12 | ONETTO NICOLE | Director | A-Award | A | Director Stock Option (Right to Buy) | 1,100 | 5.44 | 6.0K | 1,100 | D | ↗ |
| 2025-12-12 | O'CALLAGHAN BRIAN | Director | D-Return | D | Director Stock Option (Right to Buy) | 1,100 | 15.36 | 16.9K | 0 | D | ↗ |
| 2025-12-12 | Nemec Sarah | Officer | D-Return | D | Employee Stock Option (Right to Buy) | 2,199 | 61.60 | 135.5K | 0 | D | ↗ |
| 2025-12-12 | LAPORTE KATHLEEN | Director | D-Return | D | Director Stock Option (Right to Buy) | 1,250 | 32.60 | 40.8K | 0 | D | ↗ |
| 2025-12-12 | Dupont Jakob | Director | D-Return | D | Director Stock Option (Right to Buy) | 849 | 13.60 | 11.5K | 0 | D | ↗ |
| 2025-12-12 | Berner Laura | Director | A-Award | A | Director Stock Option (Right to Buy) | 1,100 | 5.44 | 6.0K | 1,100 | D | ↗ |
| 2025-12-05 | Quinn William P. | Director / Officer | P-Purchase | A | Common Stock | 125 | 4.61 | 575.88 | 2,313 | D | ↗ |
| 2025-12-05 | Nemec Sarah | Officer | P-Purchase | A | Common Stock | 125 | 4.61 | 575.88 | 1,415 | D | ↗ |
| 2025-10-22 | Yonehiro Grant | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 38,918 | D | ↗ |
| 2025-10-22 | Quinn William P. | Director / Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 42,188 | D | ↗ |
| 2025-10-22 | Nemec Sarah | Officer | A-Award | A | Common Stock | 23,000 | 0.00 | — | 23,943 | D | ↗ |
| 2025-06-06 | Quinn William P. | Director / Officer | P-Purchase | A | Common Stock | 125 | 5.49 | 686.50 | 2,188 | D | ↗ |
| 2025-06-06 | Nemec Sarah | Officer | P-Purchase | A | Common Stock | 125 | 5.49 | 686.50 | 943 | D | ↗ |
| 2025-05-27 | ONETTO NICOLE | Director | A-Award | A | Stock Option (Right to Buy) | 1,100 | 6.40 | 7.0K | 1,100 | D | ↗ |
| 2025-05-27 | O'CALLAGHAN BRIAN | Director | A-Award | A | Stock Option (Right to Buy) | 1,100 | 6.40 | 7.0K | 1,100 | D | ↗ |
| 2025-05-27 | LAPORTE KATHLEEN | Director | A-Award | A | Stock Option (Right to Buy) | 1,100 | 6.40 | 7.0K | 1,100 | D | ↗ |
| 2025-05-27 | Dupont Jakob | Director | A-Award | A | Stock Option (Right to Buy) | 1,100 | 6.40 | 7.0K | 1,100 | D | ↗ |
| 2025-05-27 | Berner Laura | Director | A-Award | A | Stock Option (Right to Buy) | 1,100 | 6.40 | 7.0K | 1,100 | D | ↗ |
| 2025-05-01 | Yonehiro Grant | Officer | A-Award | A | Stock Option (Right to Buy) | 350,000 | 0.35 | 122.9K | 350,000 | D | ↗ |
| 2025-05-01 | Quinn William P. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 700,000 | 0.35 | 245.7K | 700,000 | D | ↗ |
| 2025-05-01 | Nemec Sarah | Officer | A-Award | A | Stock Option (Right to Buy) | 226,000 | 0.35 | 79.3K | 226,000 | D | ↗ |
| 2025-05-01 | Dupont Jakob | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.35 | 7.0K | 20,000 | D | ↗ |
| 2024-12-16 | Quinn William P. | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 0.50 | 1.2K | 41,272 | D | ↗ |
| 2024-12-16 | Nemec Sarah | Officer | P-Purchase | A | Common Stock | 2,500 | 0.50 | 1.2K | 16,633 | D | ↗ |
| 2024-09-03 | Dupont Jakob | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.68 | 34.0K | 50,000 | — | ↗ |
| 2024-07-23 | Yonehiro Grant | Officer | A-Award | A | Stock Option (Right to Buy) | 155,000 | 0.73 | 113.2K | 155,000 | — | ↗ |
| 2024-07-23 | Quinn William P. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 440,000 | 0.73 | 321.2K | 440,000 | — | ↗ |
| 2024-07-23 | Nemec Sarah | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 0.73 | 65.7K | 90,000 | — | ↗ |
| 2024-06-12 | SHAH MAHENDRA | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.77 | 16.9K | 22,000 | — | ↗ |
| 2024-06-12 | ONETTO NICOLE | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.77 | 16.9K | 22,000 | — | ↗ |
| 2024-06-12 | O'CALLAGHAN BRIAN | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.77 | 16.9K | 22,000 | — | ↗ |
| 2024-06-12 | Lee Frank D. | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.77 | 16.9K | 22,000 | — | ↗ |
| 2024-06-12 | LAPORTE KATHLEEN | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.77 | 16.9K | 22,000 | — | ↗ |
| 2024-06-12 | HEALY JAMES | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.77 | 16.9K | 22,000 | — | ↗ |
| 2024-06-12 | Berner Laura | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.77 | 16.9K | 22,000 | — | ↗ |
| 2024-06-06 | Quinn William P. | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 0.64 | 1.6K | 38,772 | D | ↗ |
| 2024-06-06 | Nemec Sarah | Officer | P-Purchase | A | Common Stock | 2,500 | 0.64 | 1.6K | 13,863 | D | ↗ |
| 2024-05-15 | Nemec Sarah | Officer | — | D | Stock Option (Right to Buy) | 7,500 | 20.00 | 150.0K | 0 | — | ↗ |
| 2024-03-04 | Yonehiro Grant | Officer | A-Award | A | Stock Option (Right to Buy) | 235,000 | 1.27 | 298.5K | 235,000 | — | ↗ |
| 2024-03-04 | Schatzman Randall C | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 654,000 | 1.27 | 830.6K | 235,000 | — | ↗ |
| 2024-03-04 | Quinn William P. | Officer | A-Award | A | Stock Option (Right to Buy) | 235,000 | 1.27 | 298.5K | 235,000 | — | ↗ |
| 2024-03-04 | Perez Edith A. | Officer | A-Award | A | Stock Option (Right to Buy) | 235,000 | 1.27 | 298.5K | 235,000 | — | ↗ |
| 2023-12-31 | Yonehiro Grant | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-31 | Schatzman Randall C | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-31 | Perez Edith A. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-12 | Quinn William P. | Officer | P-Purchase | A | Common Stock | 7,500 | 0.95 | 7.1K | 36,272 | — | ↗ |
| 2023-12-06 | Quinn William P. | Officer | P-Purchase | A | Common Stock | 2,500 | 0.78 | 2.0K | 28,772 | — | ↗ |
| 2023-11-30 | ENGLEMAN EDGAR | Director | S-Sale | D | Common Stock | 108,145 | 0.86 | 92.8K | 1,821,483 | — | ↗ |
| 2023-11-29 | ENGLEMAN EDGAR | Director | S-Sale | D | Common Stock | 22,674 | 0.91 | 20.5K | 1,929,628 | — | ↗ |
| 2023-11-21 | Vivo Capital VIII, LLC | 10% Owner | S-Sale | D | Common Stock | 1,707 | 0.90 | 1.5K | 1,952,302 | — | ↗ |
| 2023-11-21 | ENGLEMAN EDGAR | Director | S-Sale | D | Common Stock | 1,707 | 0.90 | 1.5K | 1,952,302 | — | ↗ |
| 2023-11-20 | Vivo Capital VIII, LLC | 10% Owner | S-Sale | D | Common Stock | 23,443 | 0.92 | 21.6K | 113,119 | — | ↗ |
| 2023-11-20 | ENGLEMAN EDGAR | Director | S-Sale | D | Common Stock | 27,465 | 0.92 | 25.3K | 1,954,009 | — | ↗ |
| 2023-11-17 | Vivo Capital VIII, LLC | 10% Owner | S-Sale | D | Common Stock | 7,009 | 0.93 | 6.5K | 136,562 | — | ↗ |
| 2023-11-17 | ENGLEMAN EDGAR | Director | S-Sale | D | Common Stock | 8,211 | 0.93 | 7.6K | 1,981,474 | — | ↗ |
| 2023-11-16 | Vivo Capital VIII, LLC | 10% Owner | S-Sale | D | Common Stock | 7,531 | 0.96 | 7.2K | 1,989,685 | — | ↗ |
| 2023-11-16 | ENGLEMAN EDGAR | Director | S-Sale | D | Common Stock | 7,531 | 0.96 | 7.2K | 1,989,685 | — | ↗ |
| 2023-06-12 | SHAH MAHENDRA | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.63 | 40.8K | 25,000 | — | ↗ |
| 2023-06-12 | ONETTO NICOLE | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.63 | 40.8K | 25,000 | — | ↗ |
| 2023-06-12 | O'CALLAGHAN BRIAN | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.63 | 40.8K | 25,000 | — | ↗ |
| 2023-06-12 | MILLER RICHARD A MD | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.63 | 40.8K | 25,000 | — | ↗ |
| 2023-06-12 | Lee Frank D. | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.63 | 40.8K | 25,000 | — | ↗ |
| 2023-06-12 | LAPORTE KATHLEEN | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.63 | 40.8K | 25,000 | — | ↗ |
| 2023-06-12 | HEALY JAMES | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.63 | 40.8K | 25,000 | — | ↗ |
| 2023-06-12 | ENGLEMAN EDGAR | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.63 | 40.8K | 25,000 | — | ↗ |
| 2023-06-12 | Berner Laura | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.63 | 40.8K | 25,000 | — | ↗ |
| 2023-06-06 | Quinn William P. | Officer | P-Purchase | A | Common Stock | 1,829 | 1.18 | 2.2K | 26,272 | — | ↗ |
| 2023-02-27 | Yonehiro Grant | Officer | A-Award | A | Stock Option (Right to Buy) | 228,000 | 1.59 | 362.5K | 228,000 | — | ↗ |
| 2023-02-27 | Schatzman Randall C | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 728,270 | 1.59 | 1.16M | 728,270 | — | ↗ |
| 2023-02-27 | Quinn William P. | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 1.59 | 397.5K | 250,000 | — | ↗ |
| 2023-02-27 | Perez Edith A. | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 1.59 | 397.5K | 250,000 | — | ↗ |
| 2022-12-31 | Yonehiro Grant | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-31 | Schatzman Randall C | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-31 | Quinn William P. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-31 | Perez Edith A. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-14 | MILLER RICHARD A MD | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-12-14 | LAPORTE KATHLEEN | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-12-14 | Berner Laura | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-07-13 | Novo Holdings A/S | Director | S-Sale | D | COMMON STOCK | 800,000 | 2.00 | 1.60M | 3,703,991 | — | ↗ |
| 2022-06-10 | SHAH MAHENDRA | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.99 | 49.8K | 25,000 | — | ↗ |
| 2022-06-10 | ONETTO NICOLE | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-10 | O'CALLAGHAN BRIAN | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-10 | MILLER RICHARD A MD | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.99 | 49.8K | 25,000 | — | ↗ |
| 2022-06-10 | Lee Frank D. | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-10 | LAPORTE KATHLEEN | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-10 | HEALY JAMES | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.99 | 49.8K | 25,000 | — | ↗ |
| 2022-06-10 | ENGLEMAN EDGAR | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-03-24 | SHAH MAHENDRA | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 3.03 | 75.8K | 25,000 | — | ↗ |
| 2022-03-24 | ONETTO NICOLE | Director | A-Award | A | Stock Option (Right to Buy) | 12,227 | 3.03 | 37.0K | 12,227 | — | ↗ |
| 2022-03-24 | O'CALLAGHAN BRIAN | Director | A-Award | A | Stock Option (Right to Buy) | 14,071 | 0.00 | — | 14,071 | — | ↗ |
| 2022-03-24 | MILLER RICHARD A MD | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 3.03 | 75.8K | 25,000 | — | ↗ |
| 2022-03-24 | Lee Frank D. | Director | A-Award | A | Stock Option (Right to Buy) | 14,071 | 0.00 | — | 14,071 | — | ↗ |
| 2022-03-24 | LAPORTE KATHLEEN | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-03-24 | HEALY JAMES | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-03-24 | ENGLEMAN EDGAR | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-02-18 | Yonehiro Grant | Officer | A-Award | A | Stock Option (Right to Buy) | 190,000 | 3.08 | 585.2K | 190,000 | — | ↗ |
| 2022-02-18 | Schatzman Randall C | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 630,000 | 3.08 | 1.94M | 630,000 | — | ↗ |
| 2022-02-18 | Quinn William P. | Officer | A-Award | A | Stock Option (Right to Buy) | 210,000 | 3.08 | 646.8K | 210,000 | — | ↗ |
| 2022-02-18 | Perez Edith A. | Officer | A-Award | A | Stock Option (Right to Buy) | 210,000 | 3.08 | 646.8K | 210,000 | — | ↗ |
| 2022-02-18 | Dornan David | Officer | A-Award | A | Stock Option (Right to Buy) | 210,000 | 3.08 | 646.8K | 210,000 | — | ↗ |
| 2021-12-22 | Perez Edith A. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 35,714 | 2.80 | 100.0K | 189,286 | — | ↗ |
| 2021-12-14 | ONETTO NICOLE | Director | A-Award | A | Stock Option (Right to Buy) | 27,860 | 4.19 | 116.7K | 27,860 | — | ↗ |
| 2021-12-08 | Quinn William P. | Officer | P-Purchase | A | Common Stock | 5,000 | 4.72 | 23.6K | 20,154 | — | ↗ |
| 2021-12-06 | Quinn William P. | Officer | P-Purchase | A | Common Stock | 35 | 4.64 | 162.40 | 15,154 | — | ↗ |
| 2021-12-06 | Perez Edith A. | Officer | P-Purchase | A | Common Stock | 411 | 4.64 | 1.9K | 1,328 | — | ↗ |
| 2021-11-17 | O'CALLAGHAN BRIAN | Director | — | D | No securities are beneficially owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-17 | Lee Frank D. | Director | — | D | No securities are beneficially owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-04 | Quinn William P. | Officer | P-Purchase | A | Common Stock | 1,221 | 16.65 | 20.3K | 15,119 | — | ↗ |
| 2021-06-04 | Perez Edith A. | Officer | P-Purchase | A | Common Stock | 917 | 16.65 | 15.3K | 917 | — | ↗ |
| 2021-02-09 | Vivo Capital VIII, LLC | 10% Owner | P-Purchase | A | Common Stock | 150,000 | 20.00 | 3.00M | 150,000 | — | ↗ |
| 2021-02-09 | Sofinnova Venture Partners X, L.P. | 10% Owner | P-Purchase | A | Common Stock | 450,000 | 20.00 | 9.00M | 2,754,437 | — | ↗ |
| 2021-02-09 | Schatzman Randall C | Director / Officer | P-Purchase | A | Common Stock | 1,500 | 20.00 | 30.0K | 1,500 | — | ↗ |
| 2021-02-09 | SHAH MAHENDRA | Director | S-Sale | D | Common Stock | 62 | 20.00 | 1.2K | 1,448,286 | — | ↗ |
| 2021-02-09 | Quinn William P. | Officer | P-Purchase | A | Common Stock | 1,200 | 20.00 | 24.0K | 13,898 | — | ↗ |
| 2021-02-09 | Novo Holdings A/S | 10% Owner | P-Purchase | A | COMMON STOCK | 400,000 | 20.00 | 8.00M | 4,503,991 | — | ↗ |
| 2021-02-09 | LAPORTE KATHLEEN | Director | P-Purchase | A | Common Stock | 1,200 | 20.00 | 24.0K | 1,200 | — | ↗ |
| 2021-02-09 | Khanna Ashish Siri Ram | Director | P-Purchase | A | Common Stock | 1,200 | 20.00 | 24.0K | 1,200 | — | ↗ |
| 2021-02-09 | HEALY JAMES | Director | C-Conversion | D | Series C-2 Preferred Stock | 1,200,228 | 0.00 | — | 0 | — | ↗ |
| 2021-02-09 | ENGLEMAN EDGAR | Director / 10% Owner | P-Purchase | A | Common Stock | 175,733 | 20.00 | 3.51M | 1,997,216 | — | ↗ |
| 2021-02-04 | Yonehiro Grant | Officer | — | D | Stock Option (Right to Buy) | 16,444 | 2.03 | 33.4K | 0 | — | ↗ |
| 2021-02-04 | Vivo Capital VIII, LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 25,104 | — | ↗ |
| 2021-02-04 | Sofinnova Venture Partners X, L.P. | 10% Owner | — | D | Series C-1 Preferred Stock | 1,104,209 | 0.00 | — | 0 | — | ↗ |
| 2021-02-04 | Schatzman Randall C | Director / Officer | — | D | Stock Option (Right to Buy) | 791,185 | 2.73 | 2.16M | 0 | — | ↗ |
| 2021-02-04 | SHAH MAHENDRA | Director | — | I | Common Stock | 0 | 0.00 | — | 14,285 | — | ↗ |
| 2021-02-04 | Quinn William P. | Officer | — | D | Common Stock | 0 | 0.00 | — | 12,698 | — | ↗ |
| 2021-02-04 | Perez Edith A. | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 20.00 | 2.00M | 100,000 | — | ↗ |
| 2021-02-04 | Novo Holdings A/S | 10% Owner | — | D | SERIES A-1 PREFERRED STOCK | 1,096,323 | 0.00 | — | 0 | — | ↗ |
| 2021-02-04 | Moldt Peter | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-02-04 | MILLER RICHARD A MD | Director | — | D | Stock Option (Right to Buy) | 10,808 | 2.73 | 29.5K | 0 | — | ↗ |
| 2021-02-04 | LAPORTE KATHLEEN | Director | — | D | Stock Option (Right to Buy) | 27,857 | 4.41 | 122.8K | 0 | — | ↗ |
| 2021-02-04 | Khanna Ashish Siri Ram | Director | — | I | Stock Option (Right to Buy) | 10,000 | 4.34 | 43.4K | 0 | — | ↗ |
| 2021-02-04 | HEALY JAMES | Director | — | I | Series C-1 Preferred Stock | 1,104,209 | 0.00 | — | 0 | — | ↗ |
| 2021-02-04 | ENGLEMAN EDGAR | Director / 10% Owner | — | I | Series C-1 Preferred Stock | 43,901 | 0.00 | — | 0 | — | ↗ |
| 2021-02-04 | Dornan David | Officer | — | D | Stock Option (Right to Buy) | 26,460 | 2.24 | 59.3K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-6.7K
Shares Outstanding
1.92M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | William P. Quinn President, Chief Executive Officer and Chief Financial Officer | 463.5K | 191.2K | 224.4K | 3.67M | — | 10.5K | 4.56M | 85.41% | ↗ |
| 2 | 2025 | Grant Yonehiro Chief Operating Officer | 463.5K | 139.1K | 168.3K | 3.24M | — | — | 4.01M | 84.96% | ↗ |
| 3 | 2024 | Randall C. Schatzman, Ph.D. Former Chief Executive Officer | 405.4K | — | — | 653.0K | — | 380.5K | 1.44M | 45.38% | ↗ |
| 4 | 2024 | William P. Quinn President, Chief Executive Officer and Chief Financial Officer | 453.6K | 247.5K | — | 491.9K | — | 10.4K | 1.20M | 40.88% | ↗ |
| 5 | 2024 | William P. Quinn President, Chief Executive Officer and Chief Financial Officer | 453.6K | 247.5K | — | 491.9K | — | 10.4K | 1.20M | 40.88% | ↗ |
| 6 | 2024 | Grant Yonehiro Chief Operating Officer | 443.1K | 180.0K | — | 325.3K | — | — | 948.4K | 34.30% | ↗ |
| 7 | 2024 | Grant Yonehiro Chief Operating Officer | 443.1K | 180.0K | — | 325.3K | — | — | 948.4K | 34.30% | ↗ |
| 8 | 2024 | Edith Perez, M.D. Former Chief Medical Officer | 327.7K | — | — | 234.6K | — | 319.8K | 882.1K | 26.60% | ↗ |
| 9 | 2023 | Randall C. Schatzman, Ph.D. Former Chief Executive Officer | 599.1K | 263.7K | — | 877.9K | — | 9.9K | 1.75M | 50.15% | ↗ |
| 10 | 2023 | Edith Perez, M.D. Former Chief Medical Officer | 486.6K | 170.4K | — | 301.4K | — | 24.3K | 982.7K | 30.67% | ↗ |
| 11 | 2023 | William P. Quinn President, Chief Executive Officer and Chief Financial Officer | 441.8K | 159.1K | — | 301.4K | — | 9.9K | 912.2K | 33.04% | ↗ |
| 12 | 2023 | Grant Yonehiro Chief Operating Officer | 415.1K | 149.6K | — | 274.9K | — | — | 839.5K | 32.74% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| William Quinn | Chief Executive Officer, Chief Financial Officer, President, Secretary & Director | 665.2K | male |
| Grant Yonehiro | Chief Operating Officer & Chief Business Officer | 602.6K | male |
| Justin Kenkel | Senior Principal Scientist | — | male |
| Michael N. Alonso | Senior Vice President of Research | — | — |
| Sarah Nemec | Senior Vice President of Finance & Principal Accounting Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BOLT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
